Jon A. Oyer

UTX/KDM6A Loss Enhances the Malignant Phenotype of Multiple Myeloma and Sensitizes Cells to EZH2 inhibition

Teresa Ezponda, Daphné Dupéré-Richer, Christine Will et al. · Cell Reports · 2017 · 135 citations · Full text

Medicine, Molecular Biology, Oncology +17

A Mutation in Histone H2B Represents a New Class of Oncogenic Driver

Richard L. Bennett, Aditya Bele, Eliza C. Small et al. · Cancer Discovery · 2019 · 105 citations

Life Sciences, Molecular Biology, Oncology +17

Emerging Approaches for the Identification of Protein Targets of Small Molecules - A Practitioners’ Perspective

Kenneth M. Comess, Shaun M. McLoughlin, Jon A. Oyer et al. · Journal of Medicinal Chemistry · 2018 · 66 citations · Full text

Pharmacy, Medicinal Chemistry, Drug Design +14

An activating mutation of the NSD2 histone methyltransferase drives oncogenic reprogramming in acute lymphocytic leukemia

Alok Swaroop, Jon A. Oyer, Christine Will et al. · Oncogene · 2018 · 60 citations · Full text

Life Sciences, Genetics, Molecular Biology +16

C-terminal domain small phosphatase 1 and MAP kinase reciprocally control REST stability and neuronal differentiation

Edmund Nesti, Glen M. Corson, Maxwell McCleskey et al. · Proceedings of the National Academy of Sciences · 2014 · 53 citations · Full text

Life Sciences, Developmental Biology, Neuroscience +16